Financing ·
Karyopharm extends forbearance period on debt indentures to November 1
KPTIKaryopharm Therapeutics Inc.
Karyopharm Therapeutics has extended the forbearance period under its Forbearance Agreement and Limited Waiver to Indentures from October 22, 2026, to November 1, 2026. This extension was triggered by Section 19 of the agreement previously entered into on September 10, 2026. The filing does not disclose new financial terms or waivers beyond the timeline adjustment. Karyopharm Therapeutics is a biotechnology company focused on developing therapies for cancer and other diseases.